Mouse Anti-TNFRSF10A Recombinant Antibody (clone mAY4) (CAT#: HPAB-1616-FY)

Greenlee, Joshua D., et al. "Oxaliplatin resistance in colorectal cancer enhances TRAIL sensitivity via death receptor 4 upregulation and lipid raft localization." Elife 10 (2021): e67750. https://doi.org/10.7554/eLife.67750

This research investigates how oxaliplatin resistance in colorectal cancer (CRC) cells enhances their sensitivity to TRAIL-mediated apoptosis. The study demonstrates that oxaliplatin-resistant CRC cells exhibit increased susceptibility to TRAIL through upregulation of death receptor 4 (DR4) and its enhanced palmitoylation and translocation into lipid rafts. The researchers found that disrupting lipid rafts with nystatin significantly reduced TRAIL sensitivity, while stabilizing lipid rafts with resveratrol increased sensitivity. Using blood samples from metastatic CRC patients, they observed that TRAIL liposomes reduced viable circulating tumor cells by 57%, with increased DR4/lipid raft colocalization corresponding to greater oxaliplatin resistance and enhanced TRAIL liposome efficacy.
Creative Biolabs provided the anti-DR4 agonist monoclonal antibody mapatumumab (CAT# HPAB-1616-FY) for this research, which was crucial for validating the role of DR4 in TRAIL sensitization of oxaliplatin-resistant cells. The researchers used mapatumumab to demonstrate DR4 specificity, showing that oxaliplatin-resistant cells exhibited significantly increased apoptosis when treated with this antibody, paralleling the effects seen with TRAIL treatment. This contribution helped establish the causal relationship between DR4 upregulation and enhanced TRAIL sensitivity in chemoresistant colorectal cancer cells, supporting the potential of DR4-targeted therapies for patients with oxaliplatin-resistant cancer.